Begin main content

vortioxetine hydrobromide

Last Updated: June 21, 2019
Result type: Reports
Project Number: SR0611-000
Product Line: Common Drug Review

Generic Name: vortioxetine hydrobromide

Brand Name: Trintellix

Manufacturer: Lundbeck Canada Inc.

Indications: Major depressive disorder (MDD), adults.

Manufacturer Requested Reimbursement Criteria1: For the treatment of major depressive disorder (MDD) in adults.

Submission Type: New

Project Status: Active

Biosimilar: No

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted April 02, 2019
Patient group input closed May 23, 2019
Clarification:

- Patient input submission received from Canadian Mental Health Association and Canadian Mental Health Association Alberta, Hope and Me-Mood Disorders Association of Canada, Mood Disorders Society of Canada and Stigma-Free Society

Patient input summary sent for review to patient input groups June 06, 2019
Patient group comments on input summary closed June 13, 2019
Clarification:

- Patient input summary feedback received

Submission received May 01, 2019
Submission accepted for review May 15, 2019
Review initiated May 16, 2019
Draft CADTH review report(s) sent to applicant July 31, 2019
Comments from applicant on draft CADTH review report(s) received August 12, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicant September 06, 2019
Canadian Drug Expert Committee (CDEC) meeting September 18, 2019
CDEC recommendation sent to applicant and drug plans September 30, 2019
To
October 02, 2019